Skip to content
PeptideWiki.bio

Recovery

GHK-Cu

Also called Copper peptide

InjectableEvidence CEvery day
Half-life
1hours
Typical vial
50 / 100mg
Research amounts
1–2mg

per administration

Common schedule
Every day
Animal or lab only

Only animal or lab studies exist — no human study has set an amount.

Quick start

GHK-Cu at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.

Typical dose
1–2 mg per administration
How often
Every day
Where
Commonly subcutaneous Sites and rotation
Timing
No fixed time of day; kept away from other injections at the same site in reports.
What people report
Skin- and connective-tissue contexts are discussed over several weeks.
Time to steady level
~5 hours — about five half-lives
Storage
Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
Cycle length
4–8 weeks
Break between
2–4 weeks Why

A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.

Key properties

Molecular reference data.

Formula
C14H22CuN6O4
Mol. weight
401.91 Da
CAS
89030-95-5
PubChem CID
165429100

Structure note

A diagram is a reference representation of the named chemical structure. It does not establish the composition, purity, or identity of any particular vial.

Loading the structure…

Work out your draw

These numbers are a starting point — change any of them.

Vial label

Copy this into your label printer.

Published research contexts for GHK-Cu describe 12 mg per administration. Descriptive only, not a recommendation.

Cleared quickly; sub-hour estimates in plasma.

Injectable use rests on preclinical work; the human cosmetic evidence is topical and separate. No injected dose-ranging study exists, so no schedule table is shown.

What it can be combined with

How GHK-Cu is commonly discussed alongside other peptides and drugs.

Educational reference on commonly-discussed combinations, not medical advice. Combining compounds can change how each behaves — read this as a prompt to research, not a clearance.

  • KLOWKLOW already contains GHK-Cu (63% of the vial), so a standalone vial stacks on the blend's share.
    Use caution
  • BPC-157Different mechanisms; no reported interaction.
    Commonly combined
  • TB-500Different mechanisms; no reported interaction.
    Commonly combined

Modelled level — every day

1× is the peak after a single dose.

Steady-state peak
1.00× single dose

Read off the modelled curve, not an even-interval formula

Time to steady state
5hours

About five half-lives

Administrations
7/ week

Where these numbers come from

  • GHK-Cu tissue-remodelling literature (Pickart)Copper-peptide evidence is largely in-vitro and topical; injectable systemic amounts are community-derived.

Next steps

Others in recovery